Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trialZefei Jiang, Yuan Sheng, Xiaojia Wang et al.|Nature Medicine|2024Cited by 121
Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradationChengtao Sun, Guoyin Kai, Bing Han et al.|Free Radical Biology and Medicine|2022Cited by 65
TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).Zefei Jiang, Quchang Ouyang, Tao Sun et al.|Journal of Clinical Oncology|2023Cited by 5
Nano Drug Delivery Systems: Effective Therapy Strategies to Overcome Multidrug Resistance in Tumor CellsJiayan Shen, Jun Qian, Chengtao Sun et al.|ChemistrySelect|2022Cited by 2
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancerYuan Sheng, Quchang Ouyang, Tao Sun et al.|Future Oncology|2024Cited by 1